Lorlatinib Renal Impairment Study

Status:
Completed

Trial end date:
2020-02-20

Target enrollment:

Participant gender:

This is a Phase 1, open-label, multi-center, single treatment study in subjects with normal renal function and varying degrees of renal impairment.

Phase 1

Pfizer